UMB Bank n.a. Sells 1,347 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

UMB Bank n.a. lowered its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 21.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,839 shares of the company’s stock after selling 1,347 shares during the period. UMB Bank n.a.’s holdings in IDEXX Laboratories were worth $2,001,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Seilern Investment Management Ltd purchased a new position in shares of IDEXX Laboratories during the fourth quarter valued at approximately $113,104,000. Pine Haven Investment Counsel Inc increased its position in IDEXX Laboratories by 10.5% during the 4th quarter. Pine Haven Investment Counsel Inc now owns 1,075 shares of the company’s stock valued at $444,000 after buying an additional 102 shares in the last quarter. Retirement Wealth Solutions LLC purchased a new position in IDEXX Laboratories during the fourth quarter valued at $31,000. Cranbrook Wealth Management LLC boosted its holdings in IDEXX Laboratories by 7.0% in the fourth quarter. Cranbrook Wealth Management LLC now owns 382 shares of the company’s stock worth $158,000 after acquiring an additional 25 shares in the last quarter. Finally, Sax Wealth Advisors LLC grew its stake in shares of IDEXX Laboratories by 76.3% in the fourth quarter. Sax Wealth Advisors LLC now owns 1,426 shares of the company’s stock worth $590,000 after acquiring an additional 617 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insider Transactions at IDEXX Laboratories

In other news, Director Sophie V. Vandebroek sold 344 shares of the company’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the sale, the director now directly owns 905 shares in the company, valued at $380,498.20. This represents a 27.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 2.18% of the company’s stock.

IDEXX Laboratories Trading Down 2.2 %

Shares of IDXX stock opened at $419.26 on Tuesday. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $583.39. The stock has a market capitalization of $34.33 billion, a P/E ratio of 40.43, a P/E/G ratio of 3.52 and a beta of 1.36. The firm’s 50 day moving average is $423.60 and its 200 day moving average is $457.86.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The company had revenue of $975.50 million during the quarter, compared to analyst estimates of $980.32 million. During the same quarter in the previous year, the company posted $2.53 earnings per share. IDEXX Laboratories’s revenue was up 6.6% compared to the same quarter last year. Research analysts expect that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently issued reports on IDXX. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Stifel Nicolaus decreased their target price on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a report on Thursday, October 10th. Piper Sandler reiterated a “neutral” rating and set a $435.00 price target (down previously from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. JPMorgan Chase & Co. reduced their price target on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. Finally, Leerink Partners assumed coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $523.86.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.